Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Carbometyx

- PMLiVE

Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations

Lefranc has served at Ipsen since 2013, most recently as Senior Vice President

- PMLiVE

Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

- PMLiVE

Ipsen’s tumour treatment receives MHRA marketing authorisation

This is the first approval in the UK for previously treated advanced neuroendocrine tumours

- PMLiVE

Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

Treatment options following disease progression have previously been limited for many patients

- PMLiVE

Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

The number of patients newly diagnosed with NETs is believed to be on the rise

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

- PMLiVE

Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

- PMLiVE

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

- PMLiVE

BMS receives FDA approval for immunotherapy combination in liver cancer

Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

- PMLiVE

BMS granted FDA approval for immunotherapy combination in colorectal cancer

More than 154,000 cases of the disease are expected to be diagnosed in the US this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links